hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06285617 id: 2022GDRC016 briefTitle: Short-Term Versus 6-Week Prednisone in The Treatment of Subacute Thyroiditis acronym: SAT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-31 date: 2025-04-30 date: 2024-02-29 date: 2024-02-29 name: Xinqiao Hospital of Chongqing class: OTHER briefSummary: The goal of this clinical trial is to compare the efficacy and safety of short-term versus 6-week prednisone in the treatment of moderate-to-severe subacute thyroiditis. The main questions it aims to answer are: Does the short-term medication regimen reduce glucocorticoid side effects while achieving similar efficacy as the guideline treatment group? Patients with moderate-to-severe symptoms were randomly assigned to receive either 30 mg/day prednisone for 1 week, followed by 1 week of nonsteroidal anti-inflammatory drugs, or the conventional 6-week prednisone therapy in the control group. conditions: Subacute Thyroiditis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prednisone primaryPurpose: TREATMENT masking: NONE count: 600 type: ESTIMATED name: 1-week predisone+1-week celecoxib name: 6-weeks predisone measure: The difference in efficacy between the two groups at the completion. measure: Thyroid function measure: Total cholesterol (TC) measure: Triglycerides (TG) measure: Systolic blood pressure (SBP) measure: Diastolic blood pressure (DBP) measure: Parathyroid hormone (PTH) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285604 id: IRB-20230398-R briefTitle: Effect Evaluation of Different Blood Products Infusion on Neonatal Anemia overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2025-09-30 date: 2025-12-31 date: 2024-02-29 date: 2024-02-29 name: Women's Hospital School Of Medicine Zhejiang University class: OTHER briefSummary: The goal of this observational study is to evaluate the clinical efficacy of the transfusion of irradiated red blood cells, washed red blood cells, and leukocyte privative red blood cells, and to study the changes of inflammatory response before and after the transfusion of irradiated red blood cells, washed red blood cells, and leukocyte privative red blood cells in anemic neonates. The main questions it aims to answer are:
Participants will be transfused with fresh irradiated red blood cells, washed red blood cells, and leukocyte privative red blood cells respectively according to relevant clinical and laboratory indicators. conditions: Neonatal Anemia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Blood transfusion measure: Clinical efficacy of different red blood cell products transfusion in anemic neonates measure: The changes of inflammatory response before and after transfusion in anemic neonates sex: ALL minimumAge: 1 Day maximumAge: 1 Year stdAges: CHILD facility: Women's Hospital School of Medicine Zhejiang University city: Hangzhou state: Zhejiang zip: 310006 country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06285591 id: 2023-1801 briefTitle: Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors overallStatus: RECRUITING date: 2023-11-10 date: 2025-03-31 date: 2025-03-31 date: 2024-02-29 date: 2024-02-29 name: West China Hospital class: OTHER briefSummary: Radiation therapy is a common treatment modality in the management of head and neck malignancies. However, head and neck tumors often have some adverse reactions when receiving radiation therapy, such as dry mouth, change of taste, oral mucositis, etc. Among them, the incidence of oral mucositis is more than 90%, and the incidence of oral mucositis of degree 3 or more than degree 3 is more than 50%. Severe oral mucositis seriously affects the quality of survival of patients. Lactobacillus Reuteri is a natural flora of the human body that can be found in the gastrointestinal tract, skin, etc. Among them, Lactobacillus Reuteri DSM 17938 and ATCC PTA 5289 can be isolated from healthy mammals as well as poultry, and are common Lactobacillus strains marketed for the production of oral probiotics, which are commonly used in infant formulas, among others. In oral inflammatory diseases, it has been reported in the literature that Lactobacillus Reuteri DSM 17938 and ATCC PTA 5289 can reduce gingival and periodontal inflammation, mainly through the mechanisms of modulating the host inflammatory response and displacing pathogenic bacteria. In terms of safety, oral Lactobacillus Reuteri has good stability, very low pathogenic potential, and is not toxic to humans. Therefore, this study is a placebo-controlled, multi-center, open, randomized controlled clinical study to evaluate the efficacy of Lactobacillus Reuteri for the prevention of radioactive oral mucosal reactions in intensity-modulated radiotherapy for head and neck tumors, including nasopharyngeal carcinoma. conditions: Oral Mucositis (Ulcerative) Due to Radiation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 130 type: ESTIMATED name: Lactobacillus Reuteri Tablets name: Placebo-containing tablets name: Radiotherapy measure: The incidence of Severe Oral mucositis (WHO grade ≥3) measure: The time to onset of Severe Oral mucositis (WHO grade ≥3) measure: The duration of Severe Oral mucositis (WHO grade ≥3) measure: Taste function measure: Xerostomia summated xerostomia inventory (SXI) measure: Functional assessment of cancer therapy-head and neck (FACT- H&N) quality of life questionnaire measure: Adverse events measure: Oral activities scores measure: Mouth and throat soreness (MTS) scores sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West China Hospital, Sichuan University status: RECRUITING city: Chengdu state: Sichuan zip: 610041 country: China name: Xingchen Peng, PhD role: CONTACT phone: +86 18980606753 email: pxx2014@163.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06285578 id: MOST 107-2410-H-277-003 briefTitle: Effects of Probiotic and HIIT in Obese Women overallStatus: COMPLETED date: 2018-10-01 date: 2019-01-31 date: 2019-03-01 date: 2024-02-29 date: 2024-02-29 name: University of Taipei class: OTHER briefSummary: The aim of this study is to investigate whether there are the additive effects when implementing both high-intensity interval training (HIIT) and probiotics simultaneously on improving cardiorespiratory endurance and metabolism in middle-aged women. conditions: Cardiorespiratory Fitness conditions: Metabolism conditions: Anthropometry studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 47 type: ACTUAL name: Probiotics supplementation name: HIIT training name: Placebo supplementation measure: Height measure: Body weight measure: Body mass index (BMI) measure: Body fat percentage measure: Waist circumference measure: Hip circumference measure: Maximum oxygen uptake (VO2max) measure: Time to exhaustion (TTE) measure: Running economy (RE) measure: Fasting blood glucose (FBG) measure: Total cholesterol (TC) measure: Triglyceride (TG) measure: High-density lipoprotein cholesterol (HDL-C) measure: Low-density lipoprotein cholesterol (LDL-C) measure: Muscle mass measure: Fat mass measure: Bone mineral density (BMD) measure: Caloric intake sex: FEMALE minimumAge: 35 Years maximumAge: 55 Years stdAges: ADULT facility: University of Taipei city: Taipei country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06285565 id: CE390/2023 briefTitle: A Nurse-led Coaching Programme With Telemonitoring in Heart Failure acronym: INTERCOACH overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-05-01 date: 2025-05-01 date: 2024-02-29 date: 2024-02-29 name: Alberto Dal Molin class: OTHER name: Azienda Ospedaliero Universitaria Maggiore della Carita briefSummary: The goal of this pilot interventional study is to assess the feasibility and acceptability of a supportive intervention for patients affected by heart failure. The main questions it aims to answer are:
In the main trial, researchers will compare data from the intervention group with a control group to assess whether it reduces hospitalization rates and improves self-care capabilities conditions: Heart Failure conditions: Telemonitoring conditions: Hospitalizations conditions: Feasibility conditions: Mentoring studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A parallel, open-label randomized controlled feasibility study primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: The assessors will collect clinical outcomes by telephone and will be blinded to the group assignment whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Nurse-led telephone coaching intervention with home telemonitoring of vital signs measure: Recruitment rate measure: Retention rate measure: Adherence to the coaching intervention measure: Adherence to telemonitoring program measure: Completeness of data collection measure: 90- and 180-day all-cause hospital readmissions measure: 90- and 180-day heart failure-related hospital readmissions measure: 90- and 180-day Emergency Departments visits measure: 90- and 180-day General Practioner visits measure: 90- and 180-day oupatient visits measure: Self-care capacity (Self-Care of Heart Failure Index ) measure: Self Care - Self-Efficacy Scale measure: Quality of life (SF-12 scale) measure: Anxiety (Hamilton Anxiety Scale ) measure: Depression (Geriatric Depression Scale) measure: Heart Failure Somatic Perception Scale v.3 (HFSPS) measure: Mortality sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Università del Piemonte Orientale Amedeo Avogadro city: Novara zip: 28100 country: Italy name: Alberto Dal Molin, Prof role: CONTACT phone: +390321660607 email: alberto.dalmolin@med.uniupo.it name: INES BASSO role: CONTACT phone: +393927599727 email: ines.basso@uniupo.it lat: 45.44694 lon: 8.62118 hasResults: False
nctId: NCT06285552 id: 4792/0842 briefTitle: Evaluation of the Comprehensive Family Support Program (PAIF) overallStatus: RECRUITING date: 2024-02-20 date: 2026-07 date: 2026-07 date: 2024-02-29 date: 2024-04-12 name: University of Seville class: OTHER name: Gobierno de Cantabria name: Loyola University name: University of Jaen briefSummary: The goal of this study is to evaluate the effectiveness of positive parenting programs targeted to parents of toddlers, children and adolescents carried out in Cantabria (Spain).
We expect that families participating in the programs will improve their parenting competencies and their family dynamics, and that these change will stay after the program. conditions: Parenting studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants will be assigned to the manualized program according to the inclusion criteria. The comparison group will be composed of families in areas where the intervention is not available but with similar sociodemographic characteristics. primaryPurpose: PREVENTION masking: NONE count: 300 type: ESTIMATED name: Positive parenting PAIF program measure: Perception of the parental role measure: Parenting practices (Authoritative parenting style: Warmth and Support, Reasoning/Induction, Democratic Participation) measure: Parenting practices (Overreactivity and Laxness) measure: Satisfaction with the intervention measure: Children adjustment measure: Social support measure: Satisfaction with Family Life sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Consejería de Inclusión Social, Juventud, Familias E Igualdad status: RECRUITING city: Santander state: Cantabria zip: 39004 country: Spain name: JOSÉ ANGEL RODRÍGUEZ role: CONTACT phone: 942 207 756 email: rodriguez_ja@cantabria.es lat: 43.46472 lon: -3.80444 hasResults: False
nctId: NCT06285526 id: 2023/0046/OB id: 2023-A00350-45 type: REGISTRY domain: French Minister briefTitle: Glycocalyx Monitoring in Major Abdominal Surgery acronym: GLYCOCHIP overallStatus: RECRUITING date: 2022-07-05 date: 2024-07-05 date: 2025-01-05 date: 2024-02-29 date: 2024-02-29 name: University Hospital, Rouen class: OTHER briefSummary: The study of the microcirculation and glycocalyx could be an essential element in the monitoring of our patients undergoing major abdominal surgery. It would enable us to better target the objectives of anaesthesia and resuscitation, which until now have been based essentially on macro-circulatory parameters. conditions: Major Abdominal Surgery studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy name: Cephalic DuodenoPancreatectomy measure: Glycocalyx thickness measure: Glycocalyx thickness and a biological marker of tissue hypoperfusion measure: Glycocalyx thickness and a biological marker of tissue hypoxia measure: Blood cell velocity and macrocirculatory function measure: Perfused capillary density and macrocirculatory function measure: Variation of glycocalyx thickness and the daily entry-exit balance (BES) Day 1 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rouen University Hospital status: RECRUITING city: Rouen zip: 76000 country: France name: DEMAILLY Zoé, MD role: CONTACT phone: 02 32 88 24 40 phoneExt: +33 email: Zoe.Demailly@chu-rouen.fr name: Thomas CLAVIER, MD role: CONTACT phone: 02 32 88 82 92 phoneExt: +33 email: Thomas.Clavier@chu-rouen.fr lat: 49.44313 lon: 1.09932 hasResults: False
nctId: NCT06285513 id: 2021/387/OB id: 2023-A00503-42 type: REGISTRY domain: Frecnh Ministry briefTitle: Cardiovascular Metabolic Remodeling in Shock acronym: METASHOCK overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-02 date: 2026-02 date: 2024-02-29 date: 2024-02-29 name: University Hospital, Rouen class: OTHER briefSummary: The aim of the study is to increase our knowledge of energy dysfunction in the cardiovascular dysfunction observed during shock states by analysing the omics molecules involved. conditions: Shock studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Cardiac ultrasound measure: Evaluation of the prognostic capacity of the initial metabolomic profile of patients in shock sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital of Rouen city: Rouen country: France name: Grégoire JOLLY, MD role: CONTACT lat: 49.44313 lon: 1.09932 hasResults: False
nctId: NCT06285500 id: UNIQUE id: 23-5095 type: OTHER domain: University Health Network briefTitle: Umbrella Study for Single Patient Treatments in Oncology acronym: UNIQUE overallStatus: RECRUITING date: 2024-02-01 date: 2027-02-01 date: 2029-02-01 date: 2024-02-29 date: 2024-02-29 name: University Health Network, Toronto class: OTHER briefSummary: The purpose of this study is to collect data on how advanced and rare cancers respond to biomarker-based treatments. conditions: Advanced Cancer conditions: Rare Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 400 type: ESTIMATED name: Patient-specific treatments measure: Overall response rate for the overall cohorts and the number of patients accessing precision targeted therapy measure: Overall survival rate measure: Progression-free survival rate measure: Number of participants with adverse events as assessed by CTCAE v5.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Health Network, Princess Margaret Cancer Centre status: RECRUITING city: Toronto state: Ontario zip: M5G 2M9 country: Canada name: Amit Oza, Dr. role: CONTACT phone: 416 946 4450 email: amit.oza@uhn.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06285487 id: 23-1600 briefTitle: Depression in Youth Onset Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2026-06 date: 2026-06 date: 2024-02-29 date: 2024-02-29 name: University of Colorado, Denver class: OTHER briefSummary: The main purpose of this study is to compare a group-based interpersonal psychotherapy (IPT) program and a Type 2 Diabetes education program to determine if there are differences in depression levels, diabetes distress, and glycemic control in adolescents with Type 2 Diabetes. conditions: Type 2 Diabetes conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Group Program measure: Acceptability of IPT-T2D measure: Depression Changes measure: Changes in Glycemic Control sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: Children's Hospital Colorado city: Aurora state: Colorado zip: 80045 country: United States lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06285461 id: T2566/2023 briefTitle: Food Intake, Endocrine Factors and Brown Fat acronym: FoodBAT overallStatus: RECRUITING date: 2024-02-20 date: 2025-06-30 date: 2026-06-30 date: 2024-02-29 date: 2024-04-10 name: Turku University Hospital class: OTHER_GOV name: University of Turku briefSummary: This study will investigate how the acute intake of foods with high and low hedonic reward differentially affects brown adipose tissue and the interplay between gut peptides, brown fat, and the brain (gut-BAT-brain axis). conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This will be a crossover study in which participants undergo two postprandial test days with meals with high- or low-hedonic reward and two weeks of washout between interventions. primaryPurpose: PREVENTION masking: NONE count: 30 type: ESTIMATED name: Non-palatable meal name: Palatable meal measure: Brown adipose tissue metabolism measure: Changes in gut peptides measure: Differences in μ-opioid receptors in the human brain measure: Energy expenditure/Meal-induced thermogenesis measure: Visual Analogue scale (VAS) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Turku PET Centre status: RECRUITING city: Turku zip: 20520 country: Finland name: Kirsi A Virtanen role: CONTACT phone: +358407626564 email: kianvi@utu.fi lat: 60.45148 lon: 22.26869 hasResults: False
nctId: NCT06285448 id: A24-028 briefTitle: Feasibility of Lecanemab Registry and Clinical Outcome Measures overallStatus: ENROLLING_BY_INVITATION date: 2024-01-02 date: 2025-12-31 date: 2026-06-30 date: 2024-02-29 date: 2024-03-01 name: HealthPartners Institute class: OTHER briefSummary: Available FDA approved treatments for Alzheimer's disease (AD) temporary alleviate symptoms but have no bearing on overall disease progression. However, recent FDA approval of lecanemab (July 2023), a disease modifying therapy based on a phase 3 clinical trial demonstrated efficacy (cognitive) in persons with AD. Delaying the disease progression may impact not only the person living with dementia (PLWD), but also their Care Partners. It may provide the ability to achieve "life goals" as a family or may increase/reduce stress and burden on the family due to the complexity of the treatment regimen. Recent secondary analysis of this Phase 3 trial suggests quality of life showed less decline in PLWD and less increase in burden in Care Partners. The investigators propose to create a registry/database for persons living with dementia who receive lecanemab infusions at HealthPartners and their Care Partners. The investigators plan to test the feasibility of collecting outcomes data for specific patient and family focused outcomes, and outcomes that are typically not included in clinic. The outcome of this study will help in the overall goal of studying the impact of lecanemab in real-world settings in a larger cohort of PLWD and Care Partners. conditions: Alzheimer Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Lecanemab measure: Feasibility of enrollment measure: Feasibility of completing visits measure: Qualitative experience at 3 months measure: Qualitative experience at 12 months sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: HealthPartners Neuroscience Center city: Saint Paul state: Minnesota zip: 55130 country: United States lat: 44.94441 lon: -93.09327 hasResults: False
nctId: NCT06285435 id: coagulation activation in PV briefTitle: Coagulation Activation in Patients With Pemphigus overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-10 date: 2026-02 date: 2024-02-29 date: 2024-02-29 name: Assiut University class: OTHER briefSummary: Aim of work:
2. To evaluate the correlation of these markers with disease severity score by using Pemphigus Disease Area Index (PDAI) and with disease activity by measurement of anti-desmoglein 1 and 3 antibody titers. conditions: Pemphigus studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 54 type: ESTIMATED name: prothrombin fragment 1+2 measure: Comparison of coagulation activation markers in pemphigus patients with controls measure: Correlation of markers with disease severity sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06285422 id: SC262-101 briefTitle: Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-03 date: 2029-03 date: 2024-02-29 date: 2024-04-04 name: Sana Biotechnology class: INDUSTRY briefSummary: SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers. conditions: Non Hodgkin's Lymphoma conditions: Large B-cell Lymphoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: SC262 measure: Evaluate safety and tolerability of SC262 measure: Evaluate preliminary anti-tumor activity of SC262 measure: Evaluate cellular kinetics and persistence of SC262 measure: Evaluate cellular kinetics and persistence of SC262 measure: Evaluate cellular kinetics and persistence of SC262 measure: Evaluate host immunogenicity to SC262 sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285409 id: 24-02 briefTitle: Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium overallStatus: RECRUITING date: 2024-04-04 date: 2024-10 date: 2024-10 date: 2024-02-29 date: 2024-04-12 name: Samuel Lunenfeld Research Institute, Mount Sinai Hospital class: OTHER briefSummary: This study will investigate the effects of drugs called "uterotonics" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery. An uncontracted uterine state is called "uterine atony", which can lead to an excessive amount of post-delivery bleeding. Carbetocin is an uterotonic drug that works well to prevent post-delivery bleeding. In some cases, carbetocin is not enough to contract the uterus, and ongoing bleeding continues. When that happens, there are other uterotonic medications that can be used. In this study, we aim to find which uterotonic drug, amongst those available (oxytocin, carbetocin, ergometrine or carboprost), is more effective to lower the risk of post-delivery bleeding once carbetocin has already been administered.